期刊文献+

氨磺必利治疗精神分裂症阴性症状的临床效果观察 被引量:1

Observation on the clinical effect of Amisulpride in the treatment of schizophrenia patients without symptom
下载PDF
导出
摘要 目的观察氨磺必利治疗精神分裂症阴性症状的临床疗效。方法选取住院72例以阴性症状为主的精神分裂症患者,随机分为研究组和对照组,各36例,研究组给予氨磺必利,对照组给予利培酮,均口服治疗8周,采用简明精神病量表(BPRS)及阴性量表(SANS)进行临床效果分析,采用症状量表(TESS)评定不良反应。结果氨磺必利组与利培酮组总体疗效相当,氨磺必利组控制阴性症状疗效优于利培酮组,且不良反应较轻。结论氨磺必利是临床上治疗以阴性症状为主的精神分裂症的理想药物。 Objective To observe the clinical effect of Amisulpride in the treatment of schizophrenia patients with negative symptoms. Methods A total of 72 hospitalized schizophrenia patients with negative symptoms were randomly divided into study group and control group,36 cases in each group. The study group was given amisulpride,risperidone was given to the patients in control group,and the treatment lasted for 8 weeks.The Brief Psychiatric Rating Scale( BPRS) and negative symptom scale( SANS) were used to analyze the clinical effect,the symptom scale( TESS) was used to assess the adverse reactions. Results The overall efficacy of amisulpride group was similar to risperidone group. The curative effect of controlling negative symptoms in amisulpride group was superior to risperidone group,as well as mild adverse reactions. Conclusions The amisulpride is an ideal drug in the treatment of schizophrenia patients with negative symptoms.
作者 李堃 张伟
出处 《齐齐哈尔医学院学报》 2016年第31期3887-3888,共2页 Journal of Qiqihar Medical University
关键词 氨磺必利 精神分裂症 阴性症状 Amisulpride Schizophrenia Negative symptoms
  • 相关文献

参考文献5

二级参考文献88

  • 1刘俊彪,吴靖华.氯丙嗪、氯氮平、利培酮对首发精神分裂症患者糖代谢、血脂和体重的影响[J].中国神经精神疾病杂志,2004,30(4):293-295. 被引量:41
  • 2Nuss P, Tessier C. Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride [ J ]. Curr Med Res Opion,2010,26 (4) :787.
  • 3Kerwin R. From pharmacological profiles to clinical out comes [ J ]. J lnt Clin Psychopharmacol , 2000,15 (4) : 1.
  • 4Trichard C, Paillere-Martinot ML, Attar-Levy D, et al. Binding of antipsychotic drugs to cortical 5-HT2A receptors : a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients [ J ]. Am J Psychiatry, 1998,155 (4) : 505.
  • 5Miguel H E, Rogelio A, Ana F, et al, The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia:a prospective open-label study [ J]. J BMC Psychiatry,2005,5 ( 3 ) :22.
  • 6Kirschbaum KM, Hiemke C, Schmitt U. Rotarod impairment:catalepsy-like screening test for antipsychotic side effects[J], lnt J Neurosci ,2009 ,119 (10 ) :1509.
  • 7Masdrakis VG, Papadimitrion GN, Papageorgion C, et al. Development of tardive dyskinesia in a patient taking amisulpride [ J ]. J Prog Neuropsychopharmacol Biol Psychiatry,2007,31 (2) :586.
  • 8Fountoulakis KN, Panagiotidis P, Siamouli M, et al, Amisulpride-induced tardive dyskinesia [ J ]. Schizophr Res ,2006,88 ( 1-3 ) :232.
  • 9Mendhekar DN, Andrade C. Amisulpride-Induced Tardive Dyskinesia and Possible Association of Dyskinesia with Hypothyroi- dism[ J ]. J Neuropsychiatry Clin Neurosci, 2009,21 ( 1 ) : 104.
  • 10Guriz O, Ekinci AE, Orsel S, et al. Amisulpride-induced tardive dystonia: A case report [ J ]. Prog Neuropsychospharmacol Boil Psychiatry,2010,34(2) :412.

共引文献301

同被引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部